Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.
| Revenue (Most Recent Fiscal Year) | $11.02B |
| Net Income (Most Recent Fiscal Year) | $-535.60M |
| PE Ratio (Current Year Earnings Estimate) | 28.14 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 10.21 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 6.88 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2.70% |
| Net Margin (Trailing 12 Months) | -8.91% |
| Return on Equity (Trailing 12 Months) | -3.36% |
| Return on Assets (Trailing 12 Months) | -2.42% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.65 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.29 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | 1.36 |
| Book Value per Share (Most Recent Fiscal Quarter) | $63.72 |
| Earnings per Share (Most Recent Fiscal Quarter) | $3.55 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.35 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.92 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 256.80M |
| Free Float | 256.28M |
| Market Capitalization | $113.32B |
| Average Volume (Last 20 Days) | 1.21M |
| Beta (Past 60 Months) | 0.41 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 90.96% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |